Nexalin faces Nasdaq delisting over equity shortfall
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Nexalin Technology, Inc. reported that Nasdaq’s Listing Qualifications Staff notified it that stockholders’ equity of $1,519,423 as of June 30, 2026 is below the $2,500,000 minimum required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1. The company also does not meet alternative standards under Rule 5550(b) and previously received a delisting notice for not complying with the minimum bid price requirement and the $5,000,000 initial stockholders’ equity standard. A Nasdaq Hearing Panel is scheduled to consider both deficiencies on September 1, 2026, where the company plans to present its compliance plan. The company notes there is no assurance of a favorable outcome and that delisting could materially reduce liquidity, pressure the market price of its common stock, and hinder capital-raising efforts.
Positive
- None.
Negative
- Nasdaq identified a stockholders’ equity shortfall, with equity of $1,519,423 below the $2,500,000 continued listing minimum.
- The company also faces a minimum bid price deficiency and does not meet the $5,000,000 initial equity requirement, creating multiple bases for potential delisting.
- Potential delisting from The Nasdaq Capital Market could materially harm liquidity, market price of the common stock, and the company’s ability to raise capital.
Insights
Analyzing...
8-K Event Classification
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
1 item
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.
Key Figures
Stockholders’ equity: $1,519,423
Minimum stockholders’ equity for continued listing: $2,500,000
Initial stockholders’ equity requirement: $5,000,000
+2 more
5 metrics
Stockholders’ equity
$1,519,423
Reported in the Quarterly Report on Form 10-Q for the period ended June 30, 2026
Minimum stockholders’ equity for continued listing
$2,500,000
Nasdaq Listing Rule 5550(b)(1) requirement for The Nasdaq Capital Market
Initial stockholders’ equity requirement
$5,000,000
Nasdaq initial listing standard referenced for additional compliance period eligibility
Hearing date
September 1, 2026
Scheduled Nasdaq Hearing Panel date to consider listing deficiencies
Par value of common stock
$0.001 per share
Common Stock, par value $0.001 per share, trading under symbol NXL
Key Terms
Stockholders’ Equity Requirement, Minimum Bid Price Requirement, Nasdaq Listing Rule 5550(b)(1), Nasdaq Hearing Panel, +1 more
5 terms
Stockholders’ Equity Requirement financial
"the minimum stockholders’ equity requirement of $2,500,000 for continued listing"
A stockholders’ equity requirement is a minimum amount of net assets — assets minus liabilities — that a company must keep on its balance sheet to meet rules set by regulators, lenders or stock exchanges. Think of it as a required safety buffer or minimum bank balance that shows the company has enough of its own capital to absorb losses; falling below it can limit dividends, trigger covenants or risk sanctions, so investors watch it as a sign of financial health and compliance.
Minimum Bid Price Requirement market
"has not regained compliance with the minimum bid price requirement"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Listing Rule 5550(b)(1) regulatory
"for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1)"
Nasdaq Hearing Panel regulatory
"requested a hearing before a Nasdaq Hearing Panel to appeal"
A Nasdaq hearing panel is a group of independent reviewers who decide whether a publicly listed company has broken the exchange’s rules and what penalties, if any, should apply. Think of it like a neighborhood committee that reviews complaints and can impose fines, require fixes, or remove a member; for investors, the panel’s rulings can affect whether a stock keeps trading, faces suspension, or suffers reputational and price impact.
delisting market
"serves as an additional basis for delisting the Company’s securities from Nasdaq"
Delisting occurs when a company's stock is removed from a stock exchange and is no longer available for trading there. This can happen voluntarily or because the company no longer meets the exchange's requirements. For investors, delisting means they can no longer buy or sell shares of that company on the exchange, which may make it more difficult to sell their investments or affect the stock's value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Nasdaq notice did Nexalin Technology (NXL) receive on August 14, 2026?
Nasdaq staff notified Nexalin Technology that its stockholders’ equity of $1,519,423 fell below the $2,500,000 minimum required for continued listing on The Nasdaq Capital Market under Listing Rule 5550(b)(1).
What is the stockholders’ equity requirement affecting Nexalin Technology (NXL)?
To remain listed on The Nasdaq Capital Market, Nexalin must maintain stockholders’ equity of at least $2,500,000. Its most recently reported equity was $1,519,423, which Nasdaq staff cited as a continued listing deficiency.
How is Nexalin Technology (NXL) noncompliant with Nasdaq’s minimum bid price rules?
Nexalin previously received a Nasdaq staff determination for not meeting the Minimum Bid Price Requirement under Listing Rule 5550(a)(2) and for not satisfying the $5,000,000 initial stockholders’ equity requirement needed for an additional compliance period.
When is Nexalin Technology’s Nasdaq hearing scheduled and what will be considered?
A Nasdaq Hearing Panel is scheduled for September 1, 2026. The panel will consider both the stockholders’ equity deficiency and the minimum bid price deficiency when deciding whether Nexalin’s common stock may continue listing on The Nasdaq Capital Market.
What could happen to Nexalin Technology (NXL) if Nasdaq delists its common stock?
If delisted from The Nasdaq Capital Market, Nexalin expects a material adverse effect on the liquidity and market price of its common stock and on its ability to raise capital.
Does Nexalin Technology (NXL) plan to address the Nasdaq deficiencies?
Nexalin intends to present its views on the stockholders’ equity deficiency and its plan to regain compliance with the Minimum Bid Price Requirement and Stockholders’ Equity Requirement at the September 1, 2026 Nasdaq hearing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
